Patrys (ASX:PAB) has reported positive safety data from the clinical trial of its multiple myeloma drug PAT-SM6 on the first cohort of patients.
Each of the three patients in this first cohort received a total of four doses of PAT-SM6, with each dose at 0.3mg per kilogram, intravenously over a two-week period.
All of the doses of PAT-SM6 were well tolerated with no serious adverse events or dose-limiting toxicities noted in any patient.
On the basis of these positive safety data, the Data Safety Monitoring Board (DSMB) gave approval for cohort 2 to commence.
Patients in cohort 2 will each receive a minimum of 4 doses of PAT-SM6, each dose being 1mg/kilogram.
In all 3 patients, between 80-100% of their cancer cells bound PAT-SM6 strongly and specifically and there was no binding of the antibody to the non-malignant cells, confirming the absolute specificity of PAT-SM6 for cancer cells.
Post treatment with PAT-SM6, blood counts also improved significantly and more rapidly than might have been expected.
The tests also showed that patients who were administered the PAT-SM6 also were responding to previously resistant drugs, suggesting that PAT-SM6 had influence on the sensitivity of the malignant cells.
The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties.
Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage and has shown significant promise against multiple myeloma.
Cash on hand at the end of December 2012 was $6.1 million.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.